Halberd Corporation 2023 Year-End CEO Update and 2024 Goals
Jackson Center, PA, January 11, 2024 -- Halberd Corporation (OTC: HALB) made significant advances in its technology development and accomplished major business goals during the second half of 2023. 2023 ACHIEVEMENTS Halberd received from the CDC two sets of antibiotic resistant bacteria and fungi (a total of 60 samples) on which to test its proprietary laser eradication methodology. Testing at Youngstown State University (YSU) successfully eradicated every sample of the various strains of E. coli, ...
Halberd Corp. Signs Significant Revenue Sharing Agreement with Athena GTX
Athena will employ its successful history of securing government contracts, spearheading such initiatives Jackson Center, PA January 9, 2024 – Halberd Corporation (OTC-PINK: "HALB”) is thrilled to declare the formalization of a profitable revenue-sharing accord with Athena GTX, Inc., of Johnston, Iowa, (www.athenagtx.com). Athena GTX is a private enterprise specializing in providing medical care solutions tailored for first responders in both civilian and government sectors. Athena’s 20+ year history of innovative research and development funding ...
Halberd Corporation Signs Multi-Faceted Agreement with CrodenHealth.com
Peter Croden, CrodenHealth Chairman, previously executive with Pharmacia & Upjohn (Pfizer), Upjohn Canada, Upjohn Global Animal Health, NephRx, and Parnell Pharmaceuticals Holdings, Ltd. Endeavors to move Halberd forward Jackson Center, PA December 13, 2023 – Halberd Corporation (OTC-PINK: "HALB”) and CrodenHealth.com of Canada agree to produce, market, sell and distribute Halberd’s patented low dose naltrexone combo product(s) worldwide. The agreement also allows CrodenHealth.com right of first refusal regarding similar rights to future products in Halberd’s ...
Halberd Corporation Plans to Extend Research Partnership with Mississippi State University
MSU Research for Halberd to Transcend the TBI Nasal Spray Jackson Center, PA November 15, 2023 – Halberd Corporation (OTC-PINK: "HALB”) is in talks with Mississippi State University (MSU) to extend its original six-month research arrangement by an additional two years, encompassing yet-to-be defined projects. This decision stems from MSU's exceptional performance in the recent TBI Nasal Spray project, as well as the proficiency, capabilities, efficiency, and professionalism exhibited by the MSU team. Notably, the ...
Hartman, CEO and Dr. Felder, CTO of Halberd Corp Featured on The Street Reports Podcast
Jackson Center, PA, October 10, 2022 – Halberd Corporation (OTC-PINK: "HALB”) Chairman, President and CEO William A. Hartman and Chief Technology Officer, Dr Mitchell S. Felder were recently interviewed on “The Street Reports Podcast” to update the public on several of the company’s important projects: The significant results to-date of Halberd’s proprietary nasal spray testing at Mississippi State University to mitigate the adverse effects of Traumatic Brain Injury (TBI) Progress in securing a partnership with ...
Halberd’s Traumatic Brain Injury (TBI) Testing Results Replicated at Mississippi State University (MSU)
Jackson Center, PA October 4, 2023 – Halberd Corporation’s (OTC-PINK: "HALB”) proprietary nasal spray testing results to mitigate the effects of Traumatic Brain Injury (TBI) at Mississippi State University (MSU) replicated the earlier dramatic results. The latest testing results were very similar to the initial proof of concept testing: 25% reduction in Neuron Specific Enolase and 52.3% reduction in the levels of Glial Fibrillary Acid Protein compared to the control group. Neuron Specific Enolase (NSE) ...